MMED:CC News and Press, MIND MEDICINE INC. From 02/28/24

--Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of...

The growing psychedelic industry is charting its own path to commercialization instead of following cannabis’ footprints. The psychedelics industry is basing its approach on facts and research, unlike cannabis, which centered on legalization. Experts in the psychedelic field have been co...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wedn...

Research into psychedelics has increased significantly in the recent past, with growing evidence to support their therapeutic benefits for a range of disorders, among them alcoholism and depression. Now, a new study has found that people who use psychedelics such as psilocybin and LSD may experi...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management...

Hawaii recently introduced a new measure that would establish legal protections for psilocybin’s therapeutic use. Under SB 3019 , eligible patients would be allowed to possess the psychedelic and receive it under the care of a trained facilitator. The legislation, which was sponsored by...

Numerous medical professionals and first responders have urged Nevada lawmakers to reform psychedelic laws and allow the use of psychedelics in mental-health treatment. The professionals spoke to a panel of state legislators from the state’s Joint Interim Standing Committee on the Judici...

2024-01-24 09:00:41 ET Palm Beach, FL – January 24, 2024 – FN Media Group News Commentary – The coming years could see a massive shift in the U.S. government’s approach to regulating hallucinogenic drugs. Several biopharma companies are developing psy...

The state of New Jersey may soon legalize the recreational and therapeutic use of psilocybin mushrooms, following the reintroduction of a measure that was withdrawn in 2023 for revision. The measure, called the Psilocybin Behavioral Health Access and Services Act , concentrates on mental healt...

Currently, the state of California has the largest number of clinical studies in the country, making up more than 25% of registered clinical trials within the United States. Despite this, numerous studies that involve substances under Schedule I and II haven’t begun, even after obtaining...